Edge Therapeutics racks up about $72.5 mln

Berkeley Heights, New Jersey-based Edge Therapeutics, a biotech company focused on developing therapies for neurological conditions, has secured about $72.5 million in funding from two recent rounds. The company just closed $56 million in a Series C-2 funding round led by Venrock with participation from other investors that included Sofinnova Ventures, Janus Capital Management LLC, New Leaf Venture Partners and BioMed Ventures. The earlier round, which closed in December 2014, raised $16.5 million in Series C-1 funding. The investors for that round were not named. In connection to the Series C-2 round, Dr. Anders Hove of Venrock and Dr. James Healy, a managing partner at Sofinnova Ventures, have been added to Edge Therapeutics’ board of directors.

Laguna Pharmaceuticals grabs $30 mln Series B, also appoints CEO

Laguna Pharmaceuticals, formerly known as ChanRx, has closed $30 million in Series B financing. Versant Ventures and Frazier Healthcare led the round with participation from BioMed Ventures and previous backer Sante Ventures. In addition to the financing, Dr. Jerel Davis of Versant Ventures and Dr. Jamie Topper of Frazier Healthcare have been added to Laguna’s board of directors. Also, Laguna Pharmaceuticals has hired Bob Baltera as CEO. Previously, Baltera was CEO of Amira Pharmaceuticals. Laguna Pharmaceuticals is a biopharmaceutical company focused on treating atrial fibrillation and atrial flutter.


VC-backed Zosano Pharma rolls out IPO

Zosano Pharma Corp has launched its IPO after pricing its 4.5 million shares at $11 per share. The stock began trading Tuesday on the NASDAQ under the ticker symbol “ZSAN.” Ladenburg Thalmann and Roth Capital Partners are serving as lead underwriters. Based in Fremont, California, Zosano is a biopharmaceutical company focused on transdermal drug delivery. Its backers include Nomura International, BioMed Ventures, HBM BioVentures, New Enterprise Associates and ProQuest Investments.


Tracon Pharmaceuticals racks up $27 mln Series B

Tracon Pharmaceuticals has closed $27 million in Series B funding. The investors included New Enterprise Associates, BioMed Ventures, JAFCO Co., Nextech Invest, Brookline Investments, Arcus Ventures and BHP. MTS Health Partners and Wells Fargo Securities were placement agents for the financing. In addition to the funding, Paul Walker of NEA has been added to Tracon’s board of directors while Bruce Steel of BioMed Ventures will become a board observer. Based in San Diego, Tracon develops treatments for cancer and age-related macular degeneration.

VC-backed Zosano files for IPO

Zosano Pharma Corp. said Tuesday that it has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. Based in Fremont, Calif., Zosano is a biopharmaceutical firm focused on transdermal drug delivery. Its backers include Nomura International, BioMed Ventures, HBM BioVentures, NEA and ProQuest Investments.

NanoString Technologies Completes Series E

NanoString Technologies, a provider of life science tools for translational research and developer of molecular diagnostic products, has completed a $15.3 million Series E Preferred Stock issuance. New investors in the transaction included Morgan Stanley Expansion Capital and AllianceBernstein Alternative Investment Management Group. All previous venture investors participated including Clarus Ventures, Draper Fisher Jurvetson, OVP Venture Partners, GE healthymagination Fund, BioMed Ventures, and Henri Termeer.

NanoString Technologies Appoints New CFO

NanoString Technologies, a provider of life science tools and developer of molecular diagnostics, has appointed James A. Johnson as the company’s new chief financial officer. Johnson assumes this role from Wayne Burns who will remain with the company in his new position as senior vice president, operations and administration. NanoString Technologies is backed by GE, BioMed Ventures, Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

Histogenics Lines up Big-Name Life Sci VCs for Mega A-Round

Waltham, Mass.-based regenerative medicine developer Histogenics Corp. wrapped up a $49 million Series A round, the company revealed Tuesday. Sofinnova Ventures led the big round, and was joined by a litany of backers: Split Rock Partners, BioMed Ventures and FinTech GIMV Fund, L.P. invested for the first time, and were joined by ProChon Holdings BV, […]

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget